These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

270 related articles for article (PubMed ID: 27793097)

  • 1. Myocardial lipid content in Fabry disease: a combined
    Petritsch B; Köstler H; Weng AM; Horn M; Gassenmaier T; Kunz AS; Weidemann F; Wanner C; Bley TA; Beer M
    BMC Cardiovasc Disord; 2016 Oct; 16(1):205. PubMed ID: 27793097
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Non-invasive determination of myocardial lipid content in Fabry disease by 1H-MR spectroscopy.
    Petritsch B; Köstler H; Machann W; Horn M; Weng AM; Goltz JP; Hahn D; Niemann M; Weidemann F; Wanner C; Beer M
    Rofo; 2012 Nov; 184(11):1020-5. PubMed ID: 22893488
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Global longitudinal strain, myocardial storage and hypertrophy in Fabry disease.
    Vijapurapu R; Nordin S; Baig S; Liu B; Rosmini S; Augusto J; Tchan M; Hughes DA; Geberhiwot T; Moon JC; Steeds RP; Kozor R
    Heart; 2019 Mar; 105(6):470-476. PubMed ID: 30282640
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differences in Fabry cardiomyopathy between female and male patients: consequences for diagnostic assessment.
    Niemann M; Herrmann S; Hu K; Breunig F; Strotmann J; Beer M; Machann W; Voelker W; Ertl G; Wanner C; Weidemann F
    JACC Cardiovasc Imaging; 2011 Jun; 4(6):592-601. PubMed ID: 21679893
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Proposed Stages of Myocardial Phenotype Development in Fabry Disease.
    Nordin S; Kozor R; Medina-Menacho K; Abdel-Gadir A; Baig S; Sado DM; Lobascio I; Murphy E; Lachmann RH; Mehta A; Edwards NC; Ramaswami U; Steeds RP; Hughes D; Moon JC
    JACC Cardiovasc Imaging; 2019 Aug; 12(8 Pt 2):1673-1683. PubMed ID: 29778854
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Early detection of organ involvement in Fabry disease by biomarker assessment in conjunction with LGE cardiac MRI: results from the SOPHIA study.
    Weidemann F; Beer M; Kralewski M; Siwy J; Kampmann C
    Mol Genet Metab; 2019 Feb; 126(2):169-182. PubMed ID: 30594474
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Myocardial Storage, Inflammation, and Cardiac Phenotype in Fabry Disease After One Year of Enzyme Replacement Therapy.
    Nordin S; Kozor R; Vijapurapu R; Augusto JB; Knott KD; Captur G; Treibel TA; Ramaswami U; Tchan M; Geberhiwot T; Steeds RP; Hughes DA; Moon JC
    Circ Cardiovasc Imaging; 2019 Dec; 12(12):e009430. PubMed ID: 31826677
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cardiac Involvement in Myotonic Dystrophy Type 2 Patients With Preserved Ejection Fraction: Detection by Cardiovascular Magnetic Resonance.
    Schmacht L; Traber J; Grieben U; Utz W; Dieringer MA; Kellman P; Blaszczyk E; von Knobelsdorff-Brenkenhoff F; Spuler S; Schulz-Menger J
    Circ Cardiovasc Imaging; 2016 Jul; 9(7):. PubMed ID: 27363857
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Relation of burden of myocardial fibrosis to malignant ventricular arrhythmias and outcomes in Fabry disease.
    Krämer J; Niemann M; Störk S; Frantz S; Beer M; Ertl G; Wanner C; Weidemann F
    Am J Cardiol; 2014 Sep; 114(6):895-900. PubMed ID: 25073565
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Myocardial Edema, Myocyte Injury, and Disease Severity in Fabry Disease.
    Augusto JB; Nordin S; Vijapurapu R; Baig S; Bulluck H; Castelletti S; Alfarih M; Knott K; Captur G; Kotecha T; Ramaswami U; Tchan M; Geberhiwot T; Fontana M; Steeds RP; Hughes D; Kozor R; Moon JC
    Circ Cardiovasc Imaging; 2020 Mar; 13(3):e010171. PubMed ID: 32114828
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Myocardial fibrosis imaging based on T1-mapping and extracellular volume fraction (ECV) measurement in muscular dystrophy patients: diagnostic value compared with conventional late gadolinium enhancement (LGE) imaging.
    Florian A; Ludwig A; Rösch S; Yildiz H; Sechtem U; Yilmaz A
    Eur Heart J Cardiovasc Imaging; 2014 Sep; 15(9):1004-12. PubMed ID: 24686257
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tei index in fabry disease.
    Niemann M; Breunig F; Beer M; Hu K; Liu D; Emmert A; Herrmann S; Ertl G; Wanner C; Takenaka T; Tei C; Weidemann F
    J Am Soc Echocardiogr; 2011 Sep; 24(9):1026-32. PubMed ID: 21719255
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Myocardial fibrosis as the first sign of cardiac involvement in a male patient with Fabry disease: report of a clinical case and discussion on the utility of the magnetic resonance in Fabry pathology.
    Sechi A; Nucifora G; Piccoli G; Dardis A; Bembi B
    BMC Cardiovasc Disord; 2014 Jul; 14():86. PubMed ID: 25026990
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Myocardial Fibrosis and Left Ventricular Dysfunction in Duchenne Muscular Dystrophy Carriers Using Cardiac Magnetic Resonance Imaging.
    Lang SM; Shugh S; Mazur W; Sticka JJ; Rattan MS; Jefferies JL; Taylor MD
    Pediatr Cardiol; 2015 Oct; 36(7):1495-501. PubMed ID: 25976773
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cardiac Phenotype of Prehypertrophic Fabry Disease.
    Nordin S; Kozor R; Baig S; Abdel-Gadir A; Medina-Menacho K; Rosmini S; Captur G; Tchan M; Geberhiwot T; Murphy E; Lachmann R; Ramaswami U; Edwards NC; Hughes D; Steeds RP; Moon JC
    Circ Cardiovasc Imaging; 2018 Jun; 11(6):e007168. PubMed ID: 29853467
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Correlation between extent of myocardial fibrosis assessed by cardiac magnetic resonance and cardiac troponin T release in patients with nonischemic heart failure.
    Takashio S; Yamamuro M; Uemura T; Utsunomiya D; Morita K; Izumiya Y; Sugiyama S; Kojima S; Yamamoto E; Tsujita K; Tanaka T; Tayama S; Kaikita K; Hokimoto S; Yasuda O; Yamashita Y; Ogawa H
    Am J Cardiol; 2014 May; 113(10):1697-704. PubMed ID: 24698466
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [MR imaging and MR spectroscopy for characterization of cardiomyopathies in adolescents - preliminary results].
    Beer M; Buchner S; Wirbelauer J; Fuchs J; Machann W; Ritter CO; Beissert M; Darge K; Hahn D; Köstler H
    Rofo; 2007 Sep; 179(9):932-7. PubMed ID: 17705115
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characterization of Compacted Myocardial Abnormalities by Cardiac Magnetic Resonance With Native T1 Mapping in Left Ventricular Non-Compaction Patients　- A Comparison With Late Gadolinium Enhancement.
    Zhou H; Lin X; Fang L; Zhao X; Ding H; Chen W; Xu R; Bai X; Wang Y; Fang Q
    Circ J; 2016 Apr; 80(5):1210-6. PubMed ID: 27010628
    [TBL] [Abstract][Full Text] [Related]  

  • 19. T₁ mapping with cardiovascular MRI is highly sensitive for Fabry disease independent of hypertrophy and sex.
    Thompson RB; Chow K; Khan A; Chan A; Shanks M; Paterson I; Oudit GY
    Circ Cardiovasc Imaging; 2013 Sep; 6(5):637-45. PubMed ID: 23922004
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of cardiac imaging in Anderson-Fabry cardiomyopathy.
    Serra W; Marziliano N
    Cardiovasc Ultrasound; 2019 Jan; 17(1):1. PubMed ID: 30674321
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.